The PHREG Procedure

Aspirin Use=No Aspirin Use

Model Information	
Data Set	WORK.SURVIVAL
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1681
Number of Observations Used	1680

Summary of the Number of Event and Censored Values			
Total	**Event**	**Censored**	**Percent Censored**
1680	312	1368	81.43

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	**Without Covariates**	**With Covariates**
-2 LOG L	4507.960	4466.390
AIC	4507.960	4468.390
SBC	4507.960	4472.133

Testing Global Null Hypothesis: BETA=0			
Test	**Chi-Square**	**DF**	**Pr > ChiSq**
Likelihood Ratio	41.5700	1	<.0001
Score	39.6054	1	<.0001
Wald	39.9514	1	<.0001

Analysis of Maximum Likelihood Estimates						
Parameter	**DF**	**Parameter Estimate**	**Standard Error**	**Chi-Square**	**Pr > ChiSq**	**Hazard Ratio**
logtxb	1	0.48724	0.07709	39.9514	<.0001	1.628

The PHREG Procedure

Aspirin Use=No Aspirin Use

Hazard Ratios for logtxb			
Description	**Point Estimate**	**95% Wald Confidence Limits**	
logtxb Unit=1	1.628	1.400	1.893

The PHREG Procedure

Aspirin Use=Aspirin Use

Model Information	
Data Set	WORK.SURVIVAL
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1363
Number of Observations Used	1363

Summary of the Number of Event and Censored Values			
Total	**Event**	**Censored**	**Percent Censored**
1363	389	974	71.46

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	**Without Covariates**	**With Covariates**
-2 LOG L	5363.731	5338.254
AIC	5363.731	5340.254
SBC	5363.731	5344.218

Testing Global Null Hypothesis: BETA=0			
Test	**Chi-Square**	**DF**	**Pr > ChiSq**
Likelihood Ratio	25.4768	1	<.0001
Score	27.8667	1	<.0001
Wald	27.8849	1	<.0001

Analysis of Maximum Likelihood Estimates						
Parameter	**DF**	**Parameter Estimate**	**Standard Error**	**Chi-Square**	**Pr > ChiSq**	**Hazard Ratio**
logtxb	1	0.38530	0.07296	27.8849	<.0001	1.470

The PHREG Procedure

Aspirin Use=Aspirin Use

Hazard Ratios for logtxb			
Description	Point Estimate	95% Wald Confidence Limits	
logtxb Unit=1	1.470	1.274	1.696

The PHREG Procedure

Model Information	
Data Set	WORK.SURVIVAL
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	3044
Number of Observations Used	3043

Class Level Information		
Class	Value	Design Variables
q2u	Q4	1
	Q1-Q3	0

Summary of the Number of Event and Censored Values			
Total	Event	Censored	Percent Censored
3043	701	2342	76.96

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	Without Covariates	With Covariates
-2 LOG L	10870.464	10801.988
AIC	10870.464	10803.988
SBC	10870.464	10808.541

Testing Global Null Hypothesis: BETA=0			
Test	Chi-Square	DF	Pr > ChiSq
Likelihood Ratio	68.4755	1	<.0001
Score	76.6468	1	<.0001
Wald	73.8101	1	<.0001

The PHREG Procedure

Type 3 Tests			
Effect	DF	Wald Chi-Square	Pr > ChiSq
q2u	1	73.8101	<.0001

Analysis of Maximum Likelihood Estimates								
Parameter		DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	Label
q2u	Q4	1	0.67490	0.07856	73.8101	<.0001	1.964	4th Q vs Q1-3 Q4

Hazard Ratios for 4th Q vs Q1-3			
Description	Point Estimate	95% Wald Confidence Limits	
q2u Q4 vs Q1-Q3	1.964	1.684	2.291

The PHREG Procedure

Aspirin Use=No Aspirin Use

Model Information	
Data Set	WORK.SURVIVAL
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1681
Number of Observations Used	1680

Class Level Information		
Class	**Value**	**Design Variables**
q2u	**Q4**	1
	Q1-Q3	0

Summary of the Number of Event and Censored Values			
Total	**Event**	**Censored**	**Percent Censored**
1680	312	1368	81.43

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	**Without Covariates**	**With Covariates**
-2 LOG L	4507.960	4459.708
AIC	4507.960	4461.708
SBC	4507.960	4465.451

Testing Global Null Hypothesis: BETA=0			
Test	**Chi-Square**	**DF**	**Pr > ChiSq**
Likelihood Ratio	48.2521	1	<.0001
Score	55.2322	1	<.0001
Wald	52.1501	1	<.0001

The PHREG Procedure

Aspirin Use=No Aspirin Use

Type 3 Tests			
Effect	**DF**	**Wald Chi-Square**	**Pr > ChiSq**
q2u	1	52.1501	<.0001

Analysis of Maximum Likelihood Estimates								
Parameter		**DF**	**Parameter Estimate**	**Standard Error**	**Chi-Square**	**Pr > ChiSq**	**Hazard Ratio**	**Label**
q2u	**Q4**	1	0.83382	0.11546	52.1501	<.0001	2.302	4th Q vs Q1-3 Q4

Hazard Ratios for 4th Q vs Q1-3		
Description	**Point Estimate**	**95% Wald Confidence Limits**
q2u Q4 vs Q1-Q3	2.302	1.836 2.887

The PHREG Procedure

Aspirin Use=Aspirin Use

Model Information	
Data Set	WORK.SURVIVAL
Dependent Variable	days
Censoring Variable	censor
Censoring Value(s)	1
Ties Handling	BRESLOW

Number of Observations Read	1363
Number of Observations Used	1363

Class Level Information		
Class	**Value**	**Design Variables**
q2u	**Q4**	1
	Q1-Q3	0

Summary of the Number of Event and Censored Values			
Total	**Event**	**Censored**	**Percent Censored**
1363	389	974	71.46

Convergence Status
Convergence criterion (GCONV=1E-8) satisfied.

Model Fit Statistics		
Criterion	**Without Covariates**	**With Covariates**
-2 LOG L	5363.731	5340.113
AIC	5363.731	5342.113
SBC	5363.731	5346.077

Testing Global Null Hypothesis: BETA=0			
Test	**Chi-Square**	**DF**	**Pr > ChiSq**
Likelihood Ratio	23.6179	1	<.0001
Score	25.9039	1	<.0001
Wald	25.2820	1	<.0001

The PHREG Procedure

Aspirin Use=Aspirin Use

Type 3 Tests			
Effect	DF	Wald Chi-Square	Pr > ChiSq
q2u	1	25.2820	<.0001

Analysis of Maximum Likelihood Estimates								
Parameter		DF	Parameter Estimate	Standard Error	Chi-Square	Pr > ChiSq	Hazard Ratio	Label
q2u	Q4	1	0.54158	0.10771	25.2820	<.0001	1.719	4th Q vs Q1-3 Q4

Hazard Ratios for 4th Q vs Q1-3		
Description	Point Estimate	95% Wald Confidence Limits
q2u Q4 vs Q1-Q3	1.719	1.392 2.123